Screener / SEC EDGAR /CIK 0001788060 /Numbers from the XBRL of the 10-Ks
NYSE Industrials · Defense

Voyager Technologies, Inc. VOYG

Compare with peers Embed
SEC comment letters, last 20 years

1 review of VOYG's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Feb 14, 2025
Questions asked 13 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 13 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2025-02-14 to 2025-06-09 · 13 questions · 5 letters from the SEC, 4 from the company
No closing letter
SegmentsNon-GAAP measuresKey metricsChinaRevenueResults discussion (MD&A)Liquidity and cashGoodwill and impairmentCritical estimatesRisk factorsControlsAcquisitions
SEC letter of Feb 14, 2025 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Draft Registration Statement on Form S-1 submitted January 21, 2025 · Market, Industry and Other Data, page 4
SEC asked (1)
Please tell us whether you commissioned any of the third-party data included in your registration statement.
VOYG answered

No reply letter found.

Draft Registration Statement on Form S-1 submitted January 21, 2025 · Market, Industry and Other Data, page 4
SEC asked (2)
We note your disclosure that you obtained some of the market and industry data included in the registration statement from various third-party sources and that you have not independently verified the data. This statement appears to imply a disclaimer of responsibility for this information in the registration statement.
Rest of the question

Please either revise this section to remove such implication or specifically state that you are liable for all information in this registration statement. Please ensure that the identities of the sources of industry statistics disclosed in the registration statement are clear. For example, we note the following: 3. • the disclosure on page 7 that "In 2023, governments worldwide invested approximately $59 billion in space defense and security activities," • the disclosure on page 7 that "the global space economy has expanded to exceed $508 billion in 2023, representing the value of all contracts in the industry, as well as non-contracted government activities. This growth trajectory is expected to accelerate with projections surpassing $820 billion by 2032," and • the disclosure on page 15 that "Today, NASA and its international partners allocate approximately $6 billion annually to support ISS related operations and initiatives." Prospectus Summary, page 5 4. Please provide the disclosure in the Prospectus Summary in a more balanced manner. For example, we note the disclosure on pages 6 and 19 that you have executed over 1,000 successful customer space missions but do not discuss any challenges or difficulties that you have faced. Please revise as appropriate. 5. We note that you include images on pages 6-15 and 102-111. We do not object to graphics that feature your products. However, it appears that some of the graphics include imbedded disclosure regarding your business and segments that would more appropriately be included in the textual disclosure outside of the images. Please revise the graphic presentations so that they do not obscure other prospectus disclosure or give undue prominence to selected portions of your business or operations. Refer to Securities Act Forms C&DI 101.02. Our Company, page 5 6. We note you present totals that combine GAAP Revenue and Starlab Milestone cash proceeds on pages 11 and 107. It appears to us totaling these amounts essentially results in the presentation of a non-GAAP financial measure that substitutes individually tailored recognition and measurement methods. Please remove these totals or explain how you determined they comply with Question 100.04 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures. 7. Please revise to describe the Starlab joint venture arrangement in more detail, including a description of the material terms of the joint venture. In addition, please file any agreements related to the joint venture as exhibits to the prospectus. 8. We note your disclosure on page 7 that NASA awarded you a prime contract to develop Starlab, and your disclosure on page 10 that Nanoracks was awarded a Space Act Agreement as part of NASA's efforts to foster a commercial space station. Please file both agreements as exhibits and add disclosure describing the material terms of the prime contract and the Space Act Agreement. In addition, where you discuss certain program milestones of the Space Act Agreement, please expand your disclosure to describe such milestones and explain where you are in the development process. Please revise to explain if Starlab is in competition with other entities to become the commercial space station replacement for the international space station. To the extent known or applicable, please describe how the replacement will be selected and 9. disclose the number of other entities involved. In addition, please tell us what consideration you gave to expanding your disclosure in risk factors on page 37 relating to the risk that commercial and governmental customers may not choose to use Starlab or your services. Implications of Being an Emerging Growth Company, page 23 10. We note you qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and disclose on pages 24 and 68 that you have elected to avail yourselves of the provision of the JOBS Act that permit emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies; however, we also note you checked the box on the Cover Page of the filing that indicates you have elected not to use the extended transition period for complying with new or revised accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. Please revise and correct this inconsistency. Summary Consolidated Financial and Other Data, page 27 11. We note you define free cash flow as cash flow used in operating activities minus purchases of property and equipment and plus grant funding for property and equipment which differs from the typical calculation of this non-GAAP financial measure. In order to avoid potential confusion and comply with Question 102.07 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures, please revise the title of the measure you present. This comment is also applicable to your presentation of this measure in MD&A. Risk Factors, page 31 12. We note the disclosure on page F-4 of the amount of goodwill and intangibles compared to total assets as of December 31, 2023. Please include a risk factor to highlight the risks related to goodwill and intangible assets, such as writedowns. If we cannot successfully establish, maintain, protect and enforce our intellectual property, 13. We note the disclosure on page 53 that the company has "licensed, and may license in the future, intellectual property rights from third parties." Please expand the appropriate section to identify any material license agreements, discuss the material terms, and file the material agreements as exhibits. Third parties may allege that we are infringing, page 54 14. Please expand the disclosure that "We have in the past, and may in the future, be subject to claims by third parties alleging that we have infringed, misappropriated or otherwise violated their intellectual property rights" to disclose, if material, the amount of the claims. Risks related to Financial Accounting Matters We have identified material weaknesses in our internal control over financial reporting, page 15. We note you identified material weaknesses in your internal control over financial reporting. Please disclose when you expect to complete your remediation efforts and any associated material costs you incurred or expect to incur related to these efforts. Our amended and restated certificate of incorporation, page 73 16. We note your disclosure on pages 73 and 144 about the exclusive forum provision. Please revise the disclosure on pages 73 and 144 to state that there is uncertainty as to whether a court would enforce such provision. Also, if the provision applies to Securities Act claims, also state on that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act. Management's Discussion and Analysis of Financial Condition and Results of Operations Key Performance Indicators and Non-GAAP Financial Measures, page 86 17. It appears to us the current format of MD&A essentially results in non-GAAP financial measures being presented with greater prominence than the most directly comparable GAAP measures. Please ensure the format of MD&A fully complies with Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures. Critical Accounting Policies and Estimates, page 97 It appears to us your current disclosures reiterate accounting policies disclosed in the notes to your financial statements. Please revise your disclosures to more fully disclose and discuss the impact critical accounting policies and related estimates had on your financial statements, including the impact of changes in estimates, pursuant to Item 303(b)(3) of Regulation S-K. For example, we note for certain contracts you use the cost-to-cost method and revenue is recognized based on your efforts toward satisfying a performance obligation relative to the total expected efforts, which is measured using the proportion of costs incurred to date to the total cost estimate-atcompletion (EAC). We also note these projections require you to make numerous assumptions and estimates to determine EAC, are updated on a periodic basis, and, when circumstances change and warrant a modification, are revised. In addition, we note when estimates of total costs to be incurred on a contract exceed total estimates of the transaction price, a provision for the entire loss is determined at the contract level and recorded in the period in which the loss is evident. Please revise your disclosures related to revenue recognition to disclose the gross amounts of favorable and unfavorable adjustments to contract estimates you recorded during each period 18. presented and address the underlying reasons for significant adjustments. Please also revise your disclosures to quantify contract losses you recorded during each period and to disclose the estimated percentage to which loss contracts are completed and the time period when you expect loss contracts to be complete, to the extent material. It appears to us such disclosure would give more insight into the estimation process associated with your contracts and their impact on your financial statements. Intellectual Property, page 118 19. Please disclose the duration of the material patents. Consolidated Financial Statements 16. Net Sales, page F-31 20. We note your disclosures of disaggregated net sales by customer and geographic location. It appears to us, to present disaggregated net sales into categories that depict how the timing and uncertainty of sales and cash flows are affected, you should also disclose net sales recognized over time and at a point in time or explain why such disclosures are not provided. Refer to ASC 606-10-50-5 and ASC 606-10-5589 through 91. 17. Segment Reporting, page F-32 21. We note your disclosure here and under Concentration of Credit risks, on page F-10, that sales to the U.S. Government accounted for 69% of sales during the year ended December 31, 2023. In addition, you disclose on page 84, that as of December 31, 2023, approximately 79.3% of the total dollar value of your backlog related to three customers and your top ten customers represent approximately 94.3% of the total dollar value of your backlog. To help investors better understand these disclosures, please clarify the relationships between your customer disclosures, which we assume are due to the fact that all entities within the U.S. Government are required to be treated as one customer in significant customer disclosures. Exhibits 22. Please file as exhibits material contracts required by Item 601(b)(10) of Regulation S- K. For example, we note the following disclosures but the underlying agreements are not mentioned in the exhibit index: • the disclosure on pages 12 and 108 that "Currently, we are contracted to provide the advanced solid-propulsion subsystem for Lockheed Martin’s NGI contract with the U.S. Missile Defense Agency," • the disclosure on pages 12 and 109 about your "strategic partnership with Palantir," • the disclosure on pages 19 and 115 that "we are collaborating across three ISS missions to launch, operate, and validate custom camera technology being developed for their state-of-the-art MSG Sphere venues," and • the disclosure on pages 130-132 about the employment agreements. General 23. Please provide us supplemental copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, have presented or expect to present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not you retained or intend to retain copies of these communications. Please contact legal staff associated with the review of this filing to discuss how to submit the materials, if any, to us for review.

VOYG answered

No reply letter found.

SEC letter of Apr 3, 2025 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 6
SEC asked (1)
We note your response to prior comment 5. Please revise the disclosure in the graphics on page 8 to clarify the reference to "DIU."
VOYG answered

No reply letter found.

Voyager is Driven by Innovation at Scale, page 11
SEC asked (2)
We note your response to prior comment 4. Please disclose the basis for the reference on pages 11 and 115 to "more than three decades of technology development and spaceflight heritage."
VOYG answered

No reply letter found.

Summary Consolidated Financial and Other Data · Key Performance Indicators and Non-GAAP Financial Measures, page 33
SEC asked (3)
We note your reconciliation of Adjusted EBITDA for the year ended December 31, 2024 includes a non-GAAP adjustment that eliminates expenses related to Non-cash services. It is not clear to us what services these expenses relate to or why you believe excluding them from a non-GAAP performance measure, based on the nature of the consideration used to pay them, is appropriate.
Rest of the question

Please eliminate this non-GAAP adjustment or more fully explain how and why you believe it is appropriate and complies with Question 100.01 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures. Although Question 100.01 provides one example of a normal, recurring, cash operating expense necessary to operate a company’s business, please be advised that does not imply that if an expense is not paid in cash eliminating it from a non-GAAP performance would be appropriate.

VOYG answered

No reply letter found.

Summary Consolidated Financial and Other Data · Key Performance Indicators and Non-GAAP Financial Measures, page 33
SEC asked (4)
We note in addition to presenting Adjusted EBITDA you now present a non-GAAP financial measure you identify as Adjusted EBITDA excluding Starlab Space Stations in which you eliminate adjusted EBITDA related to the Starlab reportable segment from Adjusted EBITDA. It is not clear to us why you present this measure or why you believe it is useful to investor.
Rest of the question

It is also not clear to us why you believe it is appropriate to present a non-GAAP financial measure that essentially excludes the results of a VIE you are required to consolidate because you are the primary beneficiary. Please eliminate this measure or explain how and why you believe it is appropriate and complies with Question 100.04 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures.

VOYG answered

No reply letter found.

Summary Consolidated Financial and Other Data · Key Performance Indicators and Non-GAAP Financial Measures, page 33
SEC asked (5)
We note you now present a non-GAAP financial measure you identify as Innovation Spend. It is not clear to us what this measure represents or why you believe it is useful to investors. It is also not clear to us what the two non-GAAP adjustments identified as Other capitalized research and development under Section 174 and Other innovation spend actually represent and if or how they are recorded in your GAAP
Rest of the question

financial statements. In addition, similar to your presentation of adjusted EBITDA, we note you present this non-GAAP measure excluding Starlab Space Stations. Please more fully explain what these measures represent and specifically address how you use them to evaluate the performance of your business and the effectiveness of your strategies as well why you believe they comply with Question 100.04 of the SEC Staff's Compliance & Disclosure Interpretations on Non-GAAP Financial Measures. Consolidated Financial Statements 4. Acquisitions

VOYG answered

No reply letter found.

Consolidated Variable Interest Entity, page F-21
SEC asked (6)
Although the VIE may meet the definition of a business and may have issued voting equity interests, please clarify whether the VIE's assets can be used for purposes other than the settlement of the VIE's obligations. If they cannot, please provide all the disclosures required by ASC 810-10-45-25, ASC 810-10-50-2A, and ASC 810-10-503. 17. Segment Reporting, page F-35
VOYG answered

No reply letter found.

Consolidated Variable Interest Entity, page F-21
SEC asked (7)
Please confirm the Other Segment Expenses do not represent significant segment expenses categories pursuant to ASC 280-10-50-26A and instead represent other segment items pursuant to ASC 280-10-5-26B; otherwise, please tell us what consideration you gave to expanding the table to include quantified disclosure, by reportable segment, of cost of sales, research and development, selling, general, and administrative and
Rest of the question

other income or expense items based on the disclosure in footnote (1). Please also clarify how you comply with the requirement of ASC 280-10-50-26C to explain the nature of the expense information the CODM uses to manage operations, given the apparent lack of significant segment expense categories.

VOYG answered

No reply letter found.

Exhibits
SEC asked (8)
Please continue to file as exhibits material contracts required by Item 601(b)(10) of Regulation S-K. For example, we note the new disclosure on page 8 that in 2023 the company was awarded a $900 million ceiling IDIQ contract by the Air Force Life Cycle Management Center’s Architecture and Integration Directorate.
VOYG answered

No reply letter found.

SEC letter of May 6, 2025 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Consolidated Financial Statements
SEC asked
Segment Reporting, page F-36 2. We note your revised disclosure in response to prior comment 7; however, based on the lack of significant segment expense categories and amounts, please also describe the nature of the expense information your CODM uses to manage operations or clarify how your current disclosures comply with ASC 280-10-50-26C.
VOYG answered

No reply letter found.

Prospectus Summary · Joint Venture Agreement for Starlab JV, page 20
SEC asked
Please file as an exhibit the Joint Venture Agreement entered into on December 23, 2023. If the Second Amended and Restated Limited Liability Company Agreement dated April 2025 has replaced the December 2023 Joint Venture Agreement, please revise your disclosure to clarify this.
Rest of the question

In addition, we note that Section 2.9 of the April 2025 agreement states that the members intend that Starlab Space LLC shall not be a partnership or joint venture. Noting that you refer to the arrangement as a joint venture in the prospectus, please advise. Summary Consolidated Financial and Other Data, page 34 We note you provided per share disclosures; however, the amounts you disclosed do not appear to be consistent with the narrative disclosures in footnote (1). We also note 2. footnote (1) refers to the issuance of shares in this offering which appears to imply a pro forma presentation. Please ensure amounts presented and related disclosures are consistent. Also, given all the anticipated changes to your capital structure prior to the offering, please confirm or explain to us how you intend to comply with SAB Topic 4:C and if/how/where you intend to present additional pro forma per share disclosures. Key Performance Indicators and Non-GAAP Financial Measures, page 35 3. We note your response to prior comment 1, please more fully address the following: • Explain your statement that "These services and the related non-cash operating expenses are not supportive of the Company’s revenue generating activities”. Based on the description of the nature of the services being provided in the first paragraph of your response, it is not clear to us how these services would not support revenue generating activities. More specifically address the nature of the services being provided and better describe if and how the expenses being incurred relate to your operations and business strategy. • Explain your statement that the services relate to the “development of software infrastructure for use at the corporate level and in the Starlab Space Stations segment”. More specifically address the nature and extent of the infrastructure, including your accounting for any other costs related to the infrastructure that you incurred or expect to incur that are in addition to the expenses incurred under the service agreement. • Explain your expectations regarding the need to continue to obtain services subsequent to the expiration date of this service agreement. • If applicable, tell us the extent to which any services provided under the service agreement are related to the grant funding you have received or expect to receive. Principal Stockholders, page 71 4. In your next amendment, please complete the beneficial ownership table and related information, including on the cover page. Consolidated Financial Statements Condensed Consolidated Statements of Operations, page F-3 5. Please present net losses applicable to common stock on the face of the statements of operations since such amounts appear to be materially different, in quantitative terms, from reported net losses. The amounts presented should be computed for each period presented as net losses less dividends on preferred stock, including undeclared or unpaid dividends, if cumulative. Refer to SAB Topic 6:B. 10. Segment Reporting, page F-12 6. We note your response to prior 2. Given the requirements of ASC 280-10-50-32, please revise your interim financial statements to include the disclosures related to significant segment expenses required by ASC 280-10-50-26A and 50-26C, similar to the disclosures in your annual financial statements. Exhibits 7. Please file all remaining exhibits in your next amendment. Please be advised that we may have comments on such exhibits once filed.

VOYG answered
The Company respectfully advises the Staff that the arrangement governed by the Joint Venture Agreement functions as a joint venture where the parties collaborate to fulfill the agreement's stated principles. Section 2.9 of the Joint Venture Agreement is intended to clarify and disclaim certain partnership principles that might be implied by common or state law, ensuring that the parties' rights and obligations are solely defined by the Joint Venture Agreement, except for specific tax classifications detailed in Section 2.10.
Read in the reply
Prospectus Summary · Joint Venture Agreement for Starlab JV, page 20
SEC asked
We note your response to prior comment 1 and reissue in part. Please file as an exhibit the Joint Venture Agreement entered into on December 23, 2023. Summary Consolidated Financial And Other Data Per Share Information , page 36 It appears the amounts related to the Net loss per share attributable to common stockholders and the Weighted-average common shares outstanding for the periods ended March 31, 2025 and 2024
Rest of the question

have not been retro-actively adjusted to reflect the 2. stock split that occurred on June 2, 2025 and do not correspond to amounts now presented in the historical interim financial statements. Please revise. Consolidated Balance Sheet, page 38 3. It appears the amounts identified as Total deficit should be relabeled Total equity. In addition, please reconcile the historical, pro forma, and pro forma as adjusted amounts presented here to amounts presented under Capitalization on page 93. Dilution, page 95 4. Please revise the disclosures related to existing stockholders to separately present the total consideration and average price per share for common stockholders and for each separate class of preferred stockholders. Please ensure your disclosures clearly indicate the number of shares of common stock each class of preferred stock was converted into. Management Executive Officers and Board of Directors, page 152 5. We note that your disclosure in this section is as of March 31, 2025. Your disclosure should be current as the date of the document. Please revise. Exhibits 6. We note that you have removed the Air Force Solicitation exhibit from the index. We reissue prior comment 8 of our letter dated April 3, 2025 requesting that you file the IDIQ contract by the Air Force Life Cycle Management Center’s Architecture and Integration Directorate as an exhibit to the registration statement.

VOYG answered
The Company respectfully advises the Staff that the Joint Venture Agreement entered into on December 23, 2023 (the “Original Joint Venture Agreement”) was amended and restated in its entirety on April 8, 2025 (the “Current Joint Venture Agreement”) and, accordingly, the Original Joint Venture Agreement is no longer in effect. The Company has revised the disclosure on page 20 to indicate that the Original Joint Venture Agreement has been amended and restated.
Rest of the answer

The Company further advises the Staff that it filed the Current Joint Venture Agreement as Exhibit 10.11 to the Registration Statement on Form S-1 filed on May 16, 2025.

Read in the reply

Also in this review: company letter, Jun 9, 2025, company letter, Jun 9, 2025

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2025-02-14. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VOYG/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.